Bronchiectasis Exacerbation
Learn about bronchiectasis exacerbation diagnosis, including acute exacerbation of bronchiectasis and bronchiectasis flare-up. This resource provides information on clinical documentation, medical coding, and healthcare best practices for managing a bronchiectasis exacerbation. Find details on symptoms, treatment, and coding guidelines relevant for physicians, nurses, and other healthcare professionals.
Worsening of bronchiectasis symptoms like cough, mucus production, and shortness of breath.
Increased cough, thicker mucus, change in mucus color, fever, fatigue, wheezing, chest pain.
Outpatient clinic, telehealth, urgent care, emergency room, hospital admission for severe cases.
ICD-10 Code Families
Complete code families applicable to J47.1
When to use each related code
| Description | When to use |
|---|---|
| Flare-up of bronchiectasis with worsening symptoms. | Acute worsening of cough, sputum production, or shortness of breath in patients with known bronchiectasis. |
| Permanent widening of airways, leading to mucus buildup and infections. | Chronic cough, recurrent infections, and imaging showing dilated airways. Exclude other causes like cystic fibrosis. |
| Infection and inflammation of the airways, usually viral or bacterial. | Acute cough, fever, and sputum production. Consider if no history of bronchiectasis or other underlying lung disease. |
Best-practice checklist
- ✓Document sputum characteristics (color, volume, viscosity)
- ✓Record FEV1 or PEF pre/post bronchodilator, if available
- ✓Detail antibiotic treatment plan with duration and justification
- ✓Specify symptoms like cough, dyspnea, and hemoptysis
- ✓Note any related imaging findings (e.g., chest X-ray, CT)
Common pitfalls to avoid
Coding for unspecified exacerbation (J47) instead of bronchiectasis with exacerbation (J47.0) leads to lower reimbursement and inaccurate severity reflection.
COPD and asthma frequently coexist with bronchiectasis. Accurate coding of all present conditions is crucial for proper risk adjustment and care planning.
Exacerbations are often infection-driven. Failure to code the causative organism (e.g., bacterial pneumonia) impacts quality metrics and reimbursement.
Best-practice tips
- 01Document sputum changes (color, volume) for accurate ICD-10 coding (J47).
- 02Ensure CDI captures antibiotic use and response for severity & compliance.
- 03Optimize pulmonary function tests (PFTs) for accurate assessment and coding.
- 04Record patient education on airway clearance techniques for improved outcomes.
- 05Monitor and document oxygen saturation and respiratory rate for proper care.
Step-by-step checklist
- 1
1. Increased sputum volume/purulence (ICD-10 J47, SNOMED CT 48670000)
- 2
2. Worsening dyspnea/cough/fatigue (symptom assessment)
- 3
3. Change in sputum color/odor (document findings)
- 4
4. Consider chest imaging (CXR, CT) if indicated
- 5
5. Review prior exacerbations/treatment (patient history)
Ready-to-paste narrative
Patient presents with an acute exacerbation of bronchiectasis, manifested by increased sputum production, change in sputum color (yellow, green, or blood-tinged), worsening dyspnea, and increased cough frequency and severity. The patient reports a history of bronchiectasis, confirmed by prior high-resolution computed tomography (HRCT) scan of the chest. On physical examination, the patient exhibits coarse crackles and rhonchi on auscultation, primarily in the lower lung fields. Pulmonary function tests (PFTs) may demonstrate a further decline in FEV1 and FVC compared to baseline. The exacerbation is likely triggered by a respiratory tract infection, although a specific pathogen has not yet been identified. Differential diagnosis includes pneumonia, chronic obstructive pulmonary disease (COPD) exacerbation, and asthma. Treatment plan includes initiation of antibiotics targeting common respiratory pathogens, airway clearance techniques such as chest physiotherapy and postural drainage, bronchodilators via nebulizer or inhaler, and supplemental oxygen as needed. Patient education regarding pulmonary hygiene, medication adherence, and early recognition of exacerbation symptoms has been provided. Follow-up scheduled in one week to assess treatment response and adjust management as necessary. ICD-10 code J47.0, bronchiectasis with acute lower respiratory infection, is documented.
Common questions and answers
How to differentiate between a bronchiectasis exacerbation and other respiratory infections like pneumonia in a patient with underlying bronchiectasis?+
Differentiating a bronchiectasis exacerbation from other respiratory infections like pneumonia in a patient with known bronchiectasis can be challenging. While both conditions present with increased cough, sputum production, and dyspnea, some key features can help distinguish them. Exacerbations typically demonstrate a change in baseline sputum characteristics (e.g., increased volume, purulence, or hemoptysis), whereas pneumonia may present with more systemic symptoms like fever, chills, and pleuritic chest pain. Furthermore, new infiltrates on chest imaging, particularly outside the usual areas of bronchiectatic changes, may suggest pneumonia. However, overlapping features are common. Consider obtaining a sputum culture and blood tests like a complete blood count and C-reactive protein to further aid in the diagnosis and guide antibiotic selection. Explore how incorporating point-of-care testing can improve the timeliness of diagnosis and management of these exacerbations.
What are the best evidence-based antibiotic treatment options for managing an acute exacerbation of bronchiectasis in adults, considering antibiotic resistance patterns?+
Antibiotic selection for acute exacerbations of bronchiectasis should be guided by several factors, including the severity of the exacerbation, patient-specific risk factors, and local antibiotic resistance patterns. For mild to moderate exacerbations, oral antibiotics like amoxicillin-clavulanate, fluoroquinolones (e.g., levofloxacin, ciprofloxacin), or newer macrolides (e.g., azithromycin) can be effective. In severe exacerbations or cases with suspected Pseudomonas aeruginosa infection, intravenous antibiotics such as ceftazidime, piperacillin-tazobactam, or carbapenems may be necessary. It is crucial to consider local resistance patterns when selecting an antibiotic. Sputum cultures should be obtained prior to initiating antibiotic therapy to guide treatment and tailor the antibiotic choice if necessary. Consider implementing antibiotic stewardship programs to optimize antibiotic use and minimize the development of resistance. Learn more about the latest guidelines for antibiotic prescribing in bronchiectasis.
What are effective strategies for preventing future bronchiectasis flare-ups in patients with a history of recurrent exacerbations?+
Preventing future bronchiectasis flare-ups requires a multifaceted approach focusing on both managing underlying conditions and reducing exposure to triggers. Regular airway clearance techniques, including chest physiotherapy, positive expiratory pressure devices, and high-frequency chest wall oscillation, are essential for removing mucus and preventing infection. Pulmonary rehabilitation can improve lung function and exercise capacity, further reducing the risk of exacerbations. Inhaled corticosteroids may be considered for patients with concomitant asthma or airway inflammation. For patients with specific underlying causes like cystic fibrosis or immunodeficiency, targeted therapies addressing those conditions are crucial. Furthermore, vaccinations against influenza and pneumococcus are highly recommended. Finally, patient education on avoiding environmental triggers like smoke and pollutants is critical. Explore how integrating patient-reported outcomes can help monitor disease activity and personalize management strategies to prevent future exacerbations.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.